403 related articles for article (PubMed ID: 33889152)
1. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Lu X; Hu R; Peng L; Liu M; Sun Z
Front Immunol; 2021; 12():638444. PubMed ID: 33889152
[TBL] [Abstract][Full Text] [Related]
2. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
4. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
Huizinga TWJ; Torii Y; Muniz R
Rheumatol Ther; 2021 Mar; 8(1):41-61. PubMed ID: 33263165
[TBL] [Abstract][Full Text] [Related]
7. Navigating adalimumab biosimilars: an expert opinion.
Abitbol V; Benkhalifa S; Habauzit C; Marotte H
J Comp Eff Res; 2023 Nov; 12(11):e230117. PubMed ID: 37855223
[TBL] [Abstract][Full Text] [Related]
8. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.
Genovese MC; Kellner H; Arai Y; Muniz R; Alten R
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371430
[TBL] [Abstract][Full Text] [Related]
11. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
Edwards CJ; Monnet J; Ullmann M; Vlachos P; Chyrok V; Ghori V
Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.
Alten R; Markland C; Boyce M; Kawakami K; Muniz R; Genovese MC
Int J Rheum Dis; 2020 Nov; 23(11):1514-1525. PubMed ID: 32852139
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Feb; 82(1):64-70. PubMed ID: 33999266
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
[No Abstract] [Full Text] [Related]
15. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review Evaluating the Efficacy, Immunogenicity and Safety of the Biosimilar FKB327 in Treating Rheumatoid Arthritis.
Tanzeem F; Islam R
Mymensingh Med J; 2024 Jan; 33(1):313-319. PubMed ID: 38163811
[TBL] [Abstract][Full Text] [Related]
17. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
[TBL] [Abstract][Full Text] [Related]
18. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F
J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
